News Releases

Tropical Storm Francine is active in the Gulf of Mexico and is expected to develop into a hurricane. These weather conditions may impact areas in the United States, including Alabama, Arkansas, Louisiana, Mississippi, Tennessee, and Texas. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the impacted areas should expect to be contacted directly if any routes are modified or canceled.

As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.

Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.

Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he describes the untapped potential of hospital laboratories and how health systems can maximize the value of their labs.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his first article, Dr. Morice reflects on the diagnostic landscape and predicts trends that could influence the market in 2024.

Mayo Clinic Laboratories now offers the first preeclampsia-specific test (Mayo ID: PERA) that can be used to stratify patients into low or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe features. With this information, clinicians can make more informed decisions about hospitalization, monitoring, more frequent checkups, and even early delivery.

Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.

Mayo Clinic Laboratories, a leading reference laboratory, and Helix, the nation’s leading population genomics and viral surveillance company, today announced a new strategic collaboration that will provide life sciences customers access to a comprehensive joint laboratory offering for research and development initiatives across the drug development lifecycle. 

Mayo Clinic Laboratories, a leader in gastroenterology and patient care, will be exhibiting at the Crohn's & Colitis Congress, a premier conference for health care professionals and researchers interested in inflammatory bowel disease (IBD). Mayo Clinic Laboratories offers a comprehensive IBD test menu, including evaluations to diagnose, differentiate, and manage therapies to treat the condition.

As Tropical Storm Nicole approaches Florida, the Mayo Clinic Laboratories Florida location will close tonight, Nov. 9, at 7:30 p.m. ET, as a safety precaution. The location will remain closed through 7:30 p.m. ET tomorrow, Nov. 10.

Darci Block, Ph.D., co-director of the Central Clinical Lab in Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester, Minnesota, discusses how and when autoverification is used and not used to help verify the approximately 8,000 specimens that are sent to the department’s Central Clinical Lab every day.

William Morice II, M.D., Ph.D., president of Mayo Clinic Laboratories, shares his concerns about the VALID Act, which if passed would give the FDA oversight of laboratory-developed tests. VALID could hamper labs’ test development activity, increase costs for labs, and disproportionately affect smaller labs or those with fewer resources. It could also lead to more test development partnerships and lab collaboration.